Genmab A/S
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GMAB research report →
About the company
Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines.
- CEO
- Jan van de Winkel
- IPO
- 2009
- Employees
- 2,638
- HQ
- Copenhagen, DK
Price Chart
- Market Cap
- $17.51B
- P/E
- 21.50
- P/S
- 1.87
- P/B
- 3.09
- EV/EBITDA
- 15.16
- Div Yield
- 0.00%
- Gross Margin
- 38.65%
- Op Margin
- 13.67%
- Net Margin
- 8.73%
- ROE
- 14.53%
- ROIC
- 8.89%
- Revenue
- $3.72B · -82.70%
- Net Income
- $963.76M · -87.71%
- EPS
- $1.55 · -87.25%
- Op Income
- $1.25B
- FCF YoY
- -84.84%
- 52W High
- $35.43
- 52W Low
- $20.33
- 50D MA
- $26.21
- 200D MA
- $29.22
- Beta
- 0.69
- Avg Volume
- 1.85M
Get TickerSpark's AI analysis on GMAB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our GMAB coverage
Recent articles, reports, and earnings notes.
Want a deeper read on GMAB?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.